Related Experiment Video
Updated: Jun 27, 2026

07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Multi-Model Machine Learning for Survival Predictions for Castration-Resistant Prostate Cancer
Tae Jin Kim1, Jaeyun Jeong2, Young Jin Ahn3
1Department of Urology, CHA University Ilsan Medical Center, CHA University School of Medicine, Goyang 10414, Republic of Korea.
Cancers
|June 26, 2026
Summary
Machine learning models, including random survival forests (RSF) and XGBoost, accurately predict survival in castration-resistant prostate cancer (CRPC) patients. These tools offer interpretable insights for personalized treatment planning.
Area of Science:
- Oncology
- Medical Informatics
- Biostatistics
Background:
- Accurate survival prediction is crucial for optimizing treatment in castration-resistant prostate cancer (CRPC).
- Traditional models struggle with complex data interactions and limited variable inclusion.
- Machine learning (ML) offers potential for improved prognostic accuracy in CRPC.
Purpose of the Study:
- To develop and compare ML models for predicting cancer-specific mortality (CSM) and overall mortality (OM) in CRPC patients.
- To evaluate the performance and interpretability of various ML algorithms for survival prediction.
- To identify key predictors of survival outcomes in CRPC.
Main Methods:
- Retrospective analysis of 46 variables from 801 CRPC patients.
- Development of ML models: Random Survival Forests (RSF), XGBoost, LightGBM, and logistic regression.
- Performance evaluation using C-index, AUC, accuracy, precision, recall, F1-score, and SHAP for interpretability.
Main Results:
- RSF achieved the highest C-index for CSM (0.772) and OM (0.771) in the test set.
- RSF excelled in 2-year survival prediction, while XGBoost was superior for 3-year survival prediction (F1-score).
- Key predictors identified: time to first-line CRPC treatment, hemoglobin, and alkaline phosphatase levels.
Conclusions:
- RSF provides robust time-to-event prediction, and XGBoost offers complementary value for 3-year survival classification in CRPC.
- Developed ML models offer accurate and interpretable prognostic tools for personalized treatment strategies.
- External validation and integration of new therapies are needed for broader clinical application.
